(TNON) Tenon Medical, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TNON) Tenon Medical, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Tenon Medical, Inc. 4P's Marketing Mix Analysis shows what the company sells, how it prices and distributes products, and how it promotes them; the page includes a real preview of the report so you can assess style and substance before buying. Purchase the full version to receive the complete ready-to-use analysis for research, planning, or presentations.
Product
CATAMARAN SIJ Fusion System
Tenon Medical markets the CATAMARAN SIJ Fusion System as its core product and primary commercial platform for sacroiliac joint fixation and fusion procedures. In its 2025 filings, the Company continued to center revenue and sales efforts on this system, using it to drive surgeon adoption and market expansion. This makes CATAMARAN the main product behind Tenon Medical's commercial strategy.
SI joint fixation and fusion
Tenon Medical, Inc.’s SI joint fixation and fusion system is purpose-built for sacroiliac joint (SIJ) surgery, so it targets a narrow orthopedic and spine niche. The goal is to stabilize and fuse the SIJ, a market tied to the fact that SIJ pain may account for up to 15%–30% of chronic low-back pain cases. That focus supports a specialized, procedure-driven product line.
Implants and instruments
Tenon Medical, Inc.’s 2-part offering pairs implants with specialized surgical instruments, so surgeons can prepare and place the device in one workflow. That makes it a procedure-based surgical solution, not just a standalone implant. The combined system is built to support consistent placement and surgical efficiency, which matters in a market where precision drives outcomes.
Surgical implant solution
Tenon Medical, Inc. sells a surgical implant solution built for operating rooms, not consumer shelves, so demand depends on surgeon adoption and hospital purchasing cycles. The product fits physician-led workflows, where implant choice is driven by clinical need, procedure time, and reimbursement, not brand pull. As a medtech seller, Tenon Medical’s sales hinge on procedural volume and provider training.
- OR-driven, physician-led use
- Hospital and surgeon buyer base
- Clinical adoption drives sales
- Not a consumer product
Patient outcome focus
Tenon Medical frames the Catamaran SI Joint Fusion System around better patient outcomes, with a focus on stronger fixation and more reliable fusion in specialty spine care. That clinical value helps support surgeon adoption because outcomes drive procedure choice and repeat use. In recent SEC filings, Tenon is still a small-cap company, so each case matters.
- Outcome-led product story
- Fixation and fusion focus
- Supports specialty surgeon adoption
Tenon’s CATAMARAN Drives Its SIJ Fusion Strategy
Tenon Medical’s product mix centers on the CATAMARAN SIJ Fusion System, its core commercial platform for sacroiliac joint fixation and fusion. The system pairs implants with specialized instruments for surgeon-led, operating-room use, and Tenon kept it central in its 2025 filings. Its niche focus fits a market where SIJ pain may account for 15%–30% of chronic low-back pain cases.
| Metric | Detail |
|---|---|
| Core product | CATAMARAN SIJ Fusion System |
| Use | SI joint fixation and fusion |
| Buyer | Surgeons and hospitals |
| Product type | Implants plus instruments |
What is included in the product
Detailed Word Document
A concise, company-specific analysis of Tenon Medical, Inc.’s Product, Price, Place, and Promotion strategies for clear marketing insight.
Editable Excel File
Condenses Tenon Medical’s 4P’s into a clear, at-a-glance view that quickly relieves analysis overload.
Reference Sources
Provides a concise, traceable list of primary and reputable sources to validate Tenon Medical’s market, pricing, and competitive assumptions for faster, defensible due diligence.
Place
Los Gatos, California
Tenon Medical, Inc. is headquartered in Los Gatos, California, which serves as its corporate and operating base and anchors administration and business control. Los Gatos had 33,529 residents in the 2020 Census, placing Tenon Medical in the heart of Santa Clara County’s 1.9 million-person market. That location supports tight oversight of strategy, finance, and operations.
United States
The CATAMARAN SIJ Fusion System is distributed across all 50 U.S. states, giving Tenon Medical, Inc. national market coverage. The United States is the company’s primary commercial geography, so U.S. sales execution is central to growth. That broad reach supports access to the largest spine and pain-care market, where procedure volume and payer access drive demand.
Puerto Rico
Tenon Medical also distributes in Puerto Rico, widening its reach beyond the mainland and adding one more U.S. healthcare market. Puerto Rico has about 3.2 million residents, so even a modest share can matter for device access and recurring sales. This fit strengthens Tenon's geographic footprint inside the U.S. system.
Hospitals and surgical settings
Tenon Medical, Inc. reaches patients through hospitals and surgical settings, because its devices are used in procedures, not sold at retail. Access depends on surgeon adoption, hospital value-analysis approval, and facility purchasing, so the place strategy is institutional and tied to operating-room workflows.
This channel usually moves slower than consumer sales, but once a hospital adopts a device, use can repeat across many cases. For Tenon Medical, Inc., the key gatekeepers are surgeons, hospital buyers, and the procurement team that controls device access inside the surgical suite.
- Institutional channel, not retail
- Sold through hospitals and surgeons
- Purchasing depends on facility approval
- Adoption starts in the operating room
Commercial medical device footprint
Tenon Medical, Inc. builds its commercial medical device footprint through hospitals, outpatient surgical centers, and spine-focused surgeons, so its reach depends on provider adoption, not consumer demand. The company’s sales model is tied to procedure volume, surgeon training, and account conversion, which makes distribution slower but more durable once a center standardizes the device. In 2025, this B2B footprint remained centered on clinical users and procedure-based selling.
- Targets healthcare providers, not patients
- Grows through surgical center adoption
- Sales follow procedure use
Tenon Medical’s U.S.-Led Hospital Reach Drives SIJ Fusion Adoption
Tenon Medical, Inc.’s place strategy is institutional and U.S.-led: the CATAMARAN SIJ Fusion System is sold through hospitals, ambulatory surgery centers, and spine surgeons across all 50 states and Puerto Rico. That gives Tenon Medical, Inc. access to a 1.9 million-person Santa Clara County base and a 3.2 million-person Puerto Rico market, with adoption driven by operating-room approval, not retail demand.
| Place factor | 2025/2026 data |
|---|---|
| HQ | Los Gatos, California |
| U.S. reach | 50 states |
| Other market | Puerto Rico |
| Channel | Hospitals and ASCs |
Full Version Awaits
Tenon Medical, Inc. Reference Sources
The preview shown here is the actual Tenon Medical, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.
This is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.
Promotion
Surgeon education
Surgeon education is the first step in Tenon Medical, Inc.'s promotion mix because SI joint care depends on physician skill and confidence. The SI joint may account for about 15% to 30% of chronic low back pain, so teaching surgeons how the system works can lift awareness and adoption. In a small-device market, each trained physician can matter a lot for procedure volume.
Clinical data messaging
Tenon Medical, Inc. should market via clinical data messaging, because medtech buyers want proof of outcomes and procedural value. Its SIJ fixation and fusion story should stay centered on pain relief, stability, and surgeon-use metrics, backed by peer-reviewed evidence and real-world case results. In this category, evidence-based promotion matters more than broad brand claims, especially as adoption decisions often depend on clinical and economic data.
Medical conference presence
Medical conference presence is a core promotion tool for Tenon Medical, Inc. because specialty devices are best explained in person to spine and orthopedic clinicians. In 2025, major orthopedic and spine meetings still concentrated the exact buyers and gatekeepers Tenon needs, so booth demos and surgeon talks can lift product visibility and support follow-up sales calls with decision-makers.
Direct sales support
Tenon Medical, Inc. uses direct sales support as a field-led model, with reps helping hospitals and surgeons adopt its Catamaran SI joint system, train staff, and build accounts. That matters in a market where adoption depends on hands-on case support and surgeon confidence, not just product specs. One rep can move an entire hospital account from trial to routine use.
- Field teams speed surgeon training
- Account support drives hospital adoption
- Direct contact helps expand usage
Corporate and investor communications
Tenon Medical, Inc. uses SEC filings, press releases, and investor updates to keep the market informed about sales, clinical progress, and cash use. For a small public medtech company, that flow matters because it helps explain execution and supports credibility with investors and partners. It also gives shareholders a direct line to track commercial momentum and risk.
- SEC filings show formal disclosure discipline
- Releases track commercial and clinical progress
- Investor updates help build market trust
Tenon Medical’s Growth Playbook: Training, Evidence, and Surgeon Adoption
Tenon Medical, Inc. promotes Catamaran mainly through surgeon education, clinical proof, and in-person conference demos, because SI joint adoption depends on hands-on training and evidence. It pairs field sales support with account-level training to move hospitals from trial to routine use. Investor updates and SEC filings also help track execution.
| Promotion lever | Key data |
|---|---|
| Clinical need | SI joint may drive 15% to 30% of chronic low back pain |
| Go-to-market | Field-led surgeon training and conference outreach |
Price
No public list price
Tenon Medical, Inc. does not publish a consumer-style list price, so buyers cannot compare it like a retail product. For medical devices, pricing is usually negotiated through direct commercial channels with hospitals, distributors, and physicians, and the final price can vary by contract, volume, and reimbursement terms. So, the company’s price is not transparent in public filings or on its website.
Institutional pricing
Tenon Medical’s implants fit institutional pricing, where hospitals, surgery centers, and group purchasing organizations negotiate contract rates instead of using list prices. This matters because U.S. ambulatory surgery centers passed 6,000 Medicare-certified sites in recent years, so buyer power is high and pricing pressure is real. The model favors value proof: lower total procedure cost, fewer complications, and faster throughput.
Procedure-based sale
CATAMARAN SIJ Fusion System pricing is procedure-based, so Tenon Medical, Inc. sells into the full SIJ fusion episode, not just a device line item. That means hospitals judge price against operating room time, surgeon use, and total procedure economics. In 2025, this model matters more as buyers push for lower total cost per case and faster throughput.
Reimbursement sensitivity
Tenon Medical, Inc.’s SI joint implant pricing is highly sensitive to payer reimbursement because adoption usually follows coverage, not just clinical need. In the U.S., Medicare covered about 65 million people in 2025, so even small reimbursement changes can shift procedure volume and hospital buying behavior. When coverage is weak or prior auth is strict, price pressure rises and SIJ adoption slows.
- Coverage drives procedure volume.
- Medicare rules shape pricing power.
- Weak reimbursement slows SIJ adoption.
Specialty device value
Tenon Medical’s pricing for its specialty implant should track clinical value in a narrow spine and orthopedic use case, where hospitals judge payback by procedure fit, outcomes, and total case cost. The company must price against purchasing rules that often demand clear evidence of utility and budget impact.
- Specialty implant, not mass-market pricing
- Value tied to clinical utility
- Hospital approval depends on cost evidence
Tenon Medical’s Pricing Hinges on Reimbursement and Coverage
Tenon Medical, Inc. prices its CATAMARAN SIJ Fusion System through negotiated hospital and distributor contracts, not public list prices. That makes price depend on reimbursement, procedure volume, and total case cost. In 2025, Medicare covered about 65 million people, so coverage and prior auth still shape demand and pricing power.
| Price driver | 2025/2026 signal |
|---|---|
| Public list price | Not disclosed |
| Buyer base | Hospitals, ASCs, GPOs |
| Reimbursement | Key demand gate |
| Coverage base | About 65 million Medicare lives |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.